Drug Development

Phase I trials of ADX10059 initiated for anxiety and migraine

Published in Pain and Central Nervous System Week, October 17th, 2005

Addex Pharmaceuticals has commenced a phase I study with ADX10059, a compound with a novel mechanism of action, intended for the treatment of anxiety disorders and migraine.

ADX10059, a negative allosteric modulator of the metabotropic glutamate 5 (mGlu5) receptor, is one of a new class of drugs being developed by Addex, that modulate the effect of the natural activator on its specific target. Compounds with this mechanism of action have the potential for an improved side effect profile and better efficacy, compared to existing therapies.

The study will be conducted in France and is a placebo-controlled single ascending dose study in up to 48 healthy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week

Source: Pain and Central Nervous System Week (2005-10-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry